Based on the Sartorius AG VZO O.N. stock forecast from 0 analysts, the average analyst target price for Sartorius AG VZO O.N. is not available over the next 12 months. Sartorius AG VZO O.N.’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Sartorius AG VZO O.N. is Slightly Bearish, which is based on 5 positive signals and 8 negative signals. At the last closing, Sartorius AG VZO O.N.’s stock price was EUR 190.20. Sartorius AG VZO O.N.’s stock price has changed by +0.00% over the past week, +4.51% over the past month and -24.67% over the last year.
No recent analyst target price found for Sartorius AG VZO O.N.
No recent average analyst rating found for Sartorius AG VZO O.N.
Company Overview Sartorius AG VZO O.N.
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services in the United States and internationally. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors, and software apps for bioreactors and cell culture shake flask; fermenters; cell culture media products; cellcelector flex, incubator flowbox, nanowell arrays, and capillaries and tips; fluid management products; microbiology products; and Ultrafiltration membrane filters, glass and quartz microfiber filters, clarification, syringeless and in-line filters, lab chromatography, and filters and blotting papers. It also provides live-cell analysis systems, reagents and consumables, support and services, and live-cell imaging and analysis software; contract manufacturing and integration, membranes and devices, weigh cells, and data analytics, as well as connectivity, and pipetting and dispensing modules; electronic and mechanical pipettes, pipette tips, bottle-top dispensers, and pipette controllers and accessories; process automation platform and software, sensors and analyzers, biomolecule analysis tools, and data analytics software; chromatography consumables, columns, and systems; and biolayer interferometry products. In addition, the company offers water purification systems; surface plasmon resonance; lab balances, pipette calibration, mass comparators and metrology, moisture analyzers, equipment manufacturer cells, weights and weight sets, paint mixing solutions, and weighing accessories; and process filtration. Further, the company provides bioprocess consulting and engineering, biologics testing, media and process, instrument, octet service and support, and validation services. It serves the life science research, biopharmaceutical manufacturing, pharmaceutical quality control, cell and gene therapy, and applied industries. Sartorius Aktiengesellschaft was founded in 1870 and is headquartered in Göttingen, Germany. Read Less
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services in the United States and internationally. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors, and software apps ...Read More
Frequently Asked Questions About Sartorius AG VZO O.N. (SRT:XETRA) Stock
Stock Target Advisor's fundamental analysis for Sartorius AG VZO O.N.'s stock is Slightly Bearish.
SRT:XETRA stock's dividend yield is 0.41%.
Our analysis grades SRT:XETRA stock's dividend yield at F. This means that SRT:XETRA stock's dividend yield is above 29% of the stocks in the Medical Instruments & Supplies sector in the XETRA exchange.
Based on this SRT:XETRA may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on SRT:XETRA's stock to indicate what its average analyst target is.
SRT:XETRA stock's Price/Earning ratio is 153.93.
Our analysis grades SRT:XETRA stock's Price / Earning ratio at F. This means that SRT:XETRA stock's Price/Earning ratio is above 71% of the stocks in the Medical Instruments & Supplies sector in the XETRA exchange.
Based on this SRT:XETRA may be a overvalued for its sector.
The last closing price of SRT:XETRA's stock was EUR 190.20.
The most recent market capitalization for SRT:XETRA is EUR 13.20B.
Unfortunately we do not have enough analyst data on SRT:XETRA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Sartorius AG VZO O.N.'s stock.
As per our most recent records Sartorius AG VZO O.N. has 13,762 Employees.
Sartorius AG VZO O.N.'s registered address is Otto-Brenner-Strasse 20, Göttingen, Germany, 37079.
You can get more information about it from Sartorius AG VZO O.N.'s website at https://www.sartorius.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Superior Dividend Growth
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Sartorius AG VZO O.N. (SRT:XETRA) Stock
Stock Target Advisor's fundamental analysis for Sartorius AG VZO O.N.'s stock is Slightly Bearish.
SRT:XETRA stock's dividend yield is 0.41%.
Our analysis grades SRT:XETRA stock's dividend yield at F. This means that SRT:XETRA stock's dividend yield is above 29% of the stocks in the Medical Instruments & Supplies sector in the XETRA exchange.
Based on this SRT:XETRA may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on SRT:XETRA's stock to indicate what its average analyst target is.
SRT:XETRA stock's Price/Earning ratio is 153.93.
Our analysis grades SRT:XETRA stock's Price / Earning ratio at F. This means that SRT:XETRA stock's Price/Earning ratio is above 71% of the stocks in the Medical Instruments & Supplies sector in the XETRA exchange.
Based on this SRT:XETRA may be a overvalued for its sector.
The last closing price of SRT:XETRA's stock was EUR 190.20.
The most recent market capitalization for SRT:XETRA is EUR 13.20B.
Unfortunately we do not have enough analyst data on SRT:XETRA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Sartorius AG VZO O.N.'s stock.
As per our most recent records Sartorius AG VZO O.N. has 13,762 Employees.
Sartorius AG VZO O.N.'s registered address is Otto-Brenner-Strasse 20, Göttingen, Germany, 37079.
You can get more information about it from Sartorius AG VZO O.N.'s website at https://www.sartorius.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SRT:XETRA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
